Over the weekend of April 25 and 26, Abbott Laboratories took the stage at the Heart Rhythm Society 2026 annual conference in Chicago with something the cardiology world had been watching closely — late-breaking data from four clinical trials across its cardiac rhythm portfolio. The results are strong. And for patients living with atrial fibrillation, they signal a meaningful shift in how the condition will be treated going forward. Abbott presented new data across its pulsed field ablation and conduction system pacing portfolios, covering four distinct programmes: the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, new evidence for posterior wall ablation with the Volt™ PFA System, initial results from the ASCEND CSP IDE trial for the investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead, and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system.
The headline result came from the FlexPulse IDE study. Six-month data showed that 87% of patients were free from documented arrhythmias, with a high safety profile of 98.3% and no major safety events recorded. Notably, 93.3% of patients were treated exclusively with pulsed field ablation, demonstrating the effectiveness of this energy source as a standalone approach for complex AFib cases. The TactiFlex Duo catheter's defining capability is its ability to switch seamlessly between radiofrequency and pulsed field ablation within a single procedure — adapting to a patient's specific anatomy rather than applying a fixed approach.
The broader significance of these results extends beyond any single trial. Pulsed field ablation — which uses precise electrical pulses to eliminate the abnormal tissue driving irregular heart rhythms — is fundamentally different from the heat-based radiofrequency ablation that has defined cardiology practice for decades. It is faster, targets cardiac tissue more selectively, and carries a reduced risk of damage to surrounding structures. The Volt PFA System data presented at Chicago demonstrated strong safety, efficacy, and procedural efficiency for posterior wall ablation — one of the more technically demanding areas of AFib treatment. Together, the FlexPulse and Volt data are building the clinical evidence base that is accelerating cardiology's transition away from traditional heat-based surgery toward precision electrical intervention at scale.